University Hospital Llandough (Welsh: Ysbyty Llandochau Prifysgol) is a district general hospital in Llandough, Penarth, Wales. It is managed by the Cardiff and Vale University Health Board.
BACKGROUND:To model scenarios exploring potential impacts of disease-modifying therapies (DMTs) for Alzheimer's disease (AD) dementia on future health and social care costs in the United Kingdom. METHODS:A cohort Markov model was developed using population projections and published AD epidemiological data. Stage-specific transition rates (mild cognitive impairment due to AD and mild, moderate, severe AD dementia) and health and social care cost data were applied to estimate cost outcomes over 2020-2040. Potential proportion of eligible population receiving treatment (uptake) and follow-up care models (primary vs. specialist care) were elicited from expert opinion. Scenarios combined ranges of DMT efficacy estimates, uptake, and care model. DMT price was excluded due to no UK precedent. RESULTS:Without DMT access, 1,038,405 people (1.5%) were projected to have AD dementia by 2040. Under the various DMT treatment scenarios, the prevalence of AD dementia by 2040 was projected to be 34,000-98,000 cases lower. Associated cumulative cost offsets were higher, £4.4-12.9billion over 2020-2040, in scenarios where most individuals received primary care follow-up, compared with majority specialist care follow-up (-£2.3billion to +£3.2billion). Assuming DMT efficacy of 25%, 58% uptake and majority primary care follow-up cumulative cost offsets increased from £4.4billion to £10.1billion by 2040 but the UK Health Service would need to diagnose and provide DMT for over a million individuals by 2030 and two million by 2040 to achieve this. CONCLUSIONS:Potential cost offset from DMT are large but highly dependent on the model of healthcare delivery and the ability of healthcare systems to scale up diagnosis and treatment services.
Long COVID affects a substantial proportion of survivors of acute infection with severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2), who suffer a variety of symptoms that limit their quality of life and economic activity. Although the aetiology of long COVID is obscure, it appears to be a chronic inflammatory condition. Complement dysregulation is a prevalent feature of long COVID. Specifically, markers of classical, alternative, and terminal pathway activation are often elevated in patients with this condition. Here, we used a sensitive assay for mannan-binding lectin-associated serine protease-2 (MASP-2)/C1Inh complexes to analyse lectin pathway activation in a previously characterised cohort of patients with long COVID (n = 159) and healthy convalescent individuals with no persistent symptoms after infection with SARS-CoV-2 (n = 76). The data were combined with those from the most predictive complement analytes identified previously to delineate potential biomarkers of long COVID. MASP-2/C1Inh complexes were significantly elevated in patients with long COVID (p = 0.0003). Generalised linear modelling further identified an optimal set of four markers, namely iC3b (alternative pathway), TCC (terminal pathway), MASP-2/C1Inh (lectin pathway), and the complement regulator properdin, which had a receiver operating characteristic predictive power of 0.796 (95% confidence interval = 0.664-0.905). Combinations of the classical pathway markers C4, C1q, and C1s/C1Inh were poorly predictive of long COVID. These findings demonstrate that activation of the lectin complement pathway, which occurs upstream of the alternative and terminal pathways and can be inhibited therapeutically, is a salient feature of long COVID.
Background: Care home residents may require timely access to controlled drugs (CDs) for end-of-life symptom management, particularly when symptoms escalate rapidly. Delays in access or administering CDs can increase distress for residents, families, and staff. We aimed to explore UK care home professionals’ experiences of accessing and using CDs for end-of-life care, and views on the feasibility of on-site centralised CD stock. Methods: A UK-wide, cross-sectional online survey of care home staff was conducted between May and July 2025. Respondents were recruited through professional networks, social media and snowball sampling. Data were analysed using a multimethod approach combining quantitative analysis with Framework Method analysis of free-text responses. Results: Overall, 359 respondents completed the survey. Most held management roles (64.9%) and worked in care homes providing nursing care (75.8%). Among 339 respondents included in the analysis of CD access delays, 103 (30.4%) reported delays in the previous three months. Respondents reporting delays in access were more likely than those who did not to also report delays in CD administration (87.9% versus 19.5%), negative impacts on resident care (46.2% versus 5.2%), and difficulties accessing staff to administer CDs (28.6% versus 7.0%). Qualitative findings showed that rapid deterioration could expose gaps in CD access and administration pathways. Respondents perceived that timely care depended on coordinated and responsive working across care homes and external services, with delays occurring when service processes were fragmented or staffing capacity and capability were insufficient. Most respondents viewed on-site centralised stock as beneficial for resident experience (244/359, 68.0%), particularly those who had experienced delays. Qualitative responses also indicated that on-site centralised stock could improve timely access when resident-specific supply was delayed or unavailable, alongside the need for appropriate safeguards and governance. Conclusions: Improving timely CD access for end-of-life care requires action across the prescribing, supply and administration pathway, alongside ensuring adequate workforce capacity and external clinical support. On-site centralised CD stock may provide an additional route to timely access, particularly when individual-specific supply pathways are delayed or unavailable. However, implementation would require clear governance, prescribing and authorisation processes, accountability, staff training, secure storage, monitoring, and regulatory safeguards.